News
X4 Pharmaceuticals (NASDAQ:XFOR) is advancing in the biopharmaceutical field with its Phase 3 clinical trial for mavorixafor.
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback